PCSK9 and metabolic syndrome: Reduced lipoprotein lipase activity but increased low-density lipoprotein (LDL) production and pro-protein convertase subtilisin/kexin type 9 (PCSK9) expression have been associated with CKD-related dyslipidemia [127].